Bio-Techne ( (TECH) ) has released its Q1 earnings. Here is a breakdown of the information Bio-Techne presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, aiding in scientific investigations, drug discovery, and clinical testing. In its first quarter fiscal 2026 earnings report, Bio-Techne reported a slight decline in revenue but showed improvements in operating margins and earnings per share. The company completed the divestiture of its Exosome Diagnostics business to focus on non-CLIA based product lines, contributing to an adjusted operating margin increase to 29.9%. Despite a 1% decrease in revenue to $286.6 million, the company saw a rise in GAAP earnings per share from $0.21 to $0.24, and maintained an adjusted EPS of $0.42. Bio-Techne’s Protein Sciences segment experienced a slight decrease in sales, while the Diagnostics and Spatial Biology segment saw a significant improvement in operating margins. Looking ahead, Bio-Techne remains optimistic about its strategic focus and innovation capabilities, positioning itself for long-term value creation despite current market challenges.